Background: Individualized selection of antiretroviral (ARV) therapy is complex, considering drug resistance, comorbidities, drug-drug interactions, and other factors. HIV-ASSIST (www.hivassist.com) is a free, online tool that provides ARV decision support. HIV-ASSIST synthesizes patient and virus-specific attributes to rank ARV combinations based upon a composite objective of achieving viral suppression and maximizing tolerability.
Objective: To evaluate concordance of HIV-ASSIST recommendations with ARV selections of experienced HIV clinicians.
Design: Retrospective cohort study.
Patients: New and established patients at the Johns Hopkins Bartlett HIV Clinic and San Francisco Veterans Affairs HIV Clinic completing clinic visits were included. Chart reviews were conducted of the most recent clinic visit to generate HIV-ASSIST recommendations, which were compared to prescribed regimens.
Main measures: For each provider-prescribed regimen, we assessed its corresponding HIV-ASSIST "weighted score" (scale of 0 to 10 +, scores of < 2.0 are preferred), rank within HIV-ASSIST's ordered listing of ARV regimens, and concordance with the top five HIV-ASSIST ranked outputs.
Key results: Among 106 patients (16% female), 23 (22%) were ARV-naïve. HIV-ASSIST outputs for ARV-naïve patients were 100% concordant with prescribed regimens (median rank 1 [IQR 1-3], median weighted score 1.1 [IQR 1-1.2]). For 18 (17%) ARV-experienced patients with ongoing viremia, HIV-ASSIST outputs were 89% concordant with prescribed regimens (median rank 2 [IQR 1-3], median weighted score 1 [IQR 1-1.2]). For 65 (61.3%) patients that were suppressed on a current ARV regimen, HIV-ASSIST recommendations were concordant 88% of the time (median rank 1 [IQR 1-1], median weighted score 1.1 [IQR 1-1.6]). In 18% of cases, HIV-ASSIST weighted score suggested that the prescribed regimen would be considered "less preferred" (score > 2.0) than other available alternatives.
Conclusion: HIV-ASSIST is an educational decision support tool that provides ARV recommendations concordant with experienced HIV providers from two major academic centers for a diverse set of patient scenarios.
Keywords: HIV; MCDA; clinical; prescribing; tool.
Conflict of interest statement
The authors declare that they do not have a conflict of interest.
Development and Validation of HIV-ASSIST, an Online, Educational, Clinical Decision Support Tool to Guide Patient-Centered ARV Regimen Selection.J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):188-194. doi: 10.1097/QAI.0000000000002118. J Acquir Immune Defic Syndr. 2019. PMID: 31513553
New Strategies in Clinical Guideline Delivery: Randomized trial of online, interactive decision-support versus guidelines for HIV treatment selection by trainees.Clin Infect Dis. 2020 Mar 25:ciaa299. doi: 10.1093/cid/ciaa299. Online ahead of print. Clin Infect Dis. 2020. PMID: 32211758
Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.BJOG. 2013 Nov;120(12):1534-47. doi: 10.1111/1471-0528.12226. Epub 2013 Aug 7. BJOG. 2013. PMID: 23924192 Clinical Trial.
Therapeutic drug monitoring of antiretrovirals for people with HIV.Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007268. doi: 10.1002/14651858.CD007268.pub2. Cochrane Database Syst Rev. 2009. PMID: 19588422 Review.
Role of raltegravir in HIV-1 management.Ann Pharmacother. 2012 Apr;46(4):578-89. doi: 10.1345/aph.1Q616. Epub 2012 Apr 10. Ann Pharmacother. 2012. PMID: 22496475 Review.